Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen and as adjuvant treatment in patients with HER2-positive early-stage breast cancer at high risk of recurrence.
Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and hyaluronidase - in the treatment of HER2-positive breast cancers in adults.
Research Site, Buckhurst Hill, United Kingdom
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
MD Anderson Cancer Center, Houston, Texas, United States
Dana-Farber Brigham Cancer Center - Foxborough, Foxboro, Massachusetts, United States
University of Rochester Medical Center, Rochester, New York, United States
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
ICO Badalona, Badalona, Barcelona, Spain
Comp. Hosp.Univ. Santiago (Chus), Santiago De Compostela, La Coruña, Spain
Hospital Universitario del Vall d' Hebron, Barcelona, Spain
Highlands Oncology Group, Fayetteville, Arkansas, United States
University of California LA, Los Angeles, California, United States
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Winship Cancer Center Emory University, Atlanta, Georgia, United States
Johns Hopkins University, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.